Stock Price Prediction

NXTC stock has a bullish view primarily due to its promising ADC candidate, LNCB74, targeting women's cancers, with clinical trials expected to begin soon, which could drive investor optimism. Despite missing EPS estimates in Q1 and Q2 2024, the stock's potential lies in its innovative pipeline and upcoming IND filing. Analysts have set a price target of $4, indicating significant upside from its current levels.

NXTC stock has bearish sentiment due to consistent earnings misses and lack of revenue generation. The stock's price target was recently slashed from $8 to $4 by HC Wainwright, reflecting diminished confidence in its near-term prospects. With no revenue and ongoing losses, the stock faces significant downside risk.